Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021

被引：62
|
作者：
Martinez-Baz, Ivan [1 ,2 ,3 ]
Miqueleiz, Ana [3 ,4 ]
Casado, Itziar [1 ,2 ,3 ]
Navascues, Ana [3 ,4 ]
Trobajo-Sanmartin, Camino [3 ,4 ]
Burgui, Cristina [1 ,2 ,3 ]
Guevara, Marcela [1 ,2 ,3 ]
Ezpeleta, Carmen [3 ,4 ]
Castilla, Jesus [1 ,2 ,3 ]
机构：
[1] Inst Salud Publ Navarra, Pamplona, Spain
[2] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain
[3] Navarra Inst Hlth Res IdiSNA, Pamplona, Spain
[4] Complejo Hosp Navarra, Dept Clin Microbiol, Pamplona, Spain
来源：
EUROSURVEILLANCE | 2021年 / 26卷 / 21期
基金：
欧盟地平线“2020”;
关键词：
D O I：
10.2807/1560-7917.ES.2021.26.21.2100438
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
COVID-19 vaccine effectiveness was evaluated in close contacts of cases diagnosed during January-April 2021. Among 20,961 contacts, 7,240 SARS-CoV-2 infections were confirmed, with 5,467 being symptomatic and 559 leading to hospitalisations. Non-brand-specific one and two dose vaccine effectiveness were respectively, 35% (95% confidence interval (CI): 25 to 44) and 66% (95% CI: 57 to 74) against infections, 42% (95% CI: 31 to 52) and 82% (95% CI: 74 to 88) against symptomatic infection, and 72% (95% CI: 47 to 85) and 95% (95% CI: 62 to 99) against COVID-19 hospitalisation. The second dose significantly increased effectiveness. Findings support continuing complete vaccination.
引用
收藏
页数：7
相关论文
共 50 条
  • [31] Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario
    Nasreen, Sharifa
    Chung, Hannah
    He, Siyi
    Brown, Kevin A.
    Gubbay, Jonathan B.
    Buchan, Sarah A.
    Fell, Deshayne B.
    Austin, Peter C.
    Schwartz, Kevin L.
    Sundaram, Maria E.
    Calzavara, Andrew
    Chen, Branson
    Tadrous, Mina
    Wilson, Kumanan
    Wilson, Sarah E.
    Kwong, Jeffrey C.
    NATURE MICROBIOLOGY, 2022, 7 (03) : 379 - +
  • [32] Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario
    Sharifa Nasreen
    Hannah Chung
    Siyi He
    Kevin A. Brown
    Jonathan B. Gubbay
    Sarah A. Buchan
    Deshayne B. Fell
    Peter C. Austin
    Kevin L. Schwartz
    Maria E. Sundaram
    Andrew Calzavara
    Branson Chen
    Mina Tadrous
    Kumanan Wilson
    Sarah E. Wilson
    Jeffrey C. Kwong
    Nature Microbiology, 2022, 7 : 379 - 385
  • [33] SARS-CoV-2/COVID-19 Vaccines: The Promises and the Challenges Ahead
    Baldo, Vincenzo
    Reno, Chiara
    Cocchio, Silvia
    Fantini, Maria Pia
    VACCINES, 2021, 9 (01)
  • [34] COVID-19 Vaccines May Not Prevent Nasal SARS-CoV-2 Infection and Asymptomatic Transmission
    Bleier, Benjamin S.
    Ramanathan, Murugappan, Jr.
    Lane, Andrew P.
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2021, 164 (02) : 305 - 307
  • [35] Neurological complications after COVID-19 vaccines and SARS-CoV-2 infection in Lombardia (Italy)
    Boneschi, F. Martinelli
    Bortolan, F.
    Leoni, O.
    Ercolanoni, M.
    Corona, A.
    Colacioppo, P.
    Vrabie, P.
    Cideni, F.
    Priori, A.
    Salmaggi, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 500 - 500
  • [36] DPP4 inhibition: Preventing SARS-CoV-2 infection and/or progression of COVID-19?
    Strollo, Rocky
    Pozzilli, Paolo
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2020, 36 (08)
  • [37] Should Breakthrough SARS-CoV-2 Infection Affect Our Confidence in the COVID-19 Vaccines?
    Lamptey, Emmanuel
    INFECTION AND CHEMOTHERAPY, 2021, 53 (04): : 676 - 685
  • [38] CLUSTERING OF COVID-19 VACCINES BY SARS-CoV-2 INFECTION LEVEL AFTER TWO VACCINATIONS
    Kiladze, A. B.
    JP JOURNAL OF BIOSTATISTICS, 2023, 23 (01) : 1 - 10
  • [39] Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection
    Patone, Martina
    Handunnetthi, Lahiru
    Saatci, Defne
    Pan, Jiafeng
    Katikireddi, Srinivasa Vittal
    Razvi, Saif
    Hunt, David
    Mei, Xue W.
    Dixon, Sharon
    Zaccardi, Francesco
    Khunti, Kamlesh
    Watkinson, Peter
    Coupland, Carol A. C.
    Doidge, James
    Harrison, David A.
    Ravanan, Rommel
    Sheikh, Aziz
    Robertson, Chris
    Hippisley-Cox, Julia
    NATURE MEDICINE, 2021, 27 (12) : 2144 - +
  • [40] Durability of COVID-19 humoral immunity post infection and different SARS-COV-2 vaccines
    Alroqi, Fayhan
    Barhoumi, Tlili
    Masuadi, Emad
    Nogoud, Maysa
    Aljedaie, Modhi
    Abu-Jaffal, Ahmad Selah
    Bokhamseen, Maha
    Saud, Myaad
    Hakami, Maumonah
    Arabi, Yaseen M.
    Nasr, Amre
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2024, 17 (04) : 704 - 711
12345